Published Technical Disclosure Archive

Advanced Implantable Canister for Optimized Biotherapeutic Agent Delivery

Publication ID: 24-11857670_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Advanced Implantable Canister for Optimized Biotherapeutic Agent Delivery,” Published Technical Disclosure No. 24-11857670_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857670_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,670.

Summary of the Inventive Concept

An implantable canister with dynamically adjustable pore size, enhanced biocompatibility, and real-time monitoring capabilities for efficient delivery of cellular and biotherapeutic agents.

Background and Problem Solved

The original implantable cellular and biotherapeutic agent delivery canister patent (FIELD OF INVENTION) has limitations in terms of controlled agent release, biocompatibility, and adaptability to changing tissue environments. The new inventive concept addresses these limitations by introducing a dynamically adjustable pore size, nanoscale bicontinuous morphology for enhanced biocompatibility, and real-time monitoring capabilities.

Detailed Description of the Inventive Concept

The advanced implantable canister features a nanoporous structure with dynamically adjustable pore size, allowing for optimal agent release in response to changes in the surrounding tissue environment. The canister is fabricated using a 3D printing process, enabling customized, patient-specific pore structures. Additionally, the canister is coated with a nanoscale, bicontinuous morphology that promotes cellular adhesion and tissue integration, enhancing biocompatibility. A microfluidic channel integrated into the canister enables real-time monitoring of agent release and tissue response. Furthermore, the canister is designed with a self-healing mechanism that repairs damage to the nanoporous structure, ensuring optimal agent release.

Novelty and Inventive Step

The new claims introduce a dynamically adjustable pore size, nanoscale bicontinuous morphology, and real-time monitoring capabilities, which are not present in the original patent. These features provide a significant improvement in controlled agent release, biocompatibility, and adaptability to changing tissue environments, thereby constituting a non-obvious inventive step.

Alternative Embodiments and Variations

Alternative embodiments of the advanced implantable canister could include varying the material composition, incorporating additional sensors for real-time monitoring, or integrating with other implantable devices. Variations of the self-healing mechanism could also be explored, such as using different materials or geometries.

Potential Commercial Applications and Market

The advanced implantable canister has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the areas of regenerative medicine, tissue engineering, and personalized healthcare. Target markets include hospitals, research institutions, and pharmaceutical companies.

CPC Classifications

SectionClassGroup
A A61 A61K9/0024
A A61 A61F2/022
A A61 A61K31/337
A A61 A61K31/397
A A61 A61K31/436
A A61 A61K31/65
A A61 A61K31/7036
A A61 A61K35/28
A A61 A61K38/14
A A61 A61K38/1866
A A61 A61K38/22
A A61 A61K39/395
A A61 A61K47/02
A A61 A61M39/0247
A A61 A61M2039/027
A A61 A61M2039/0261
A A61 A61M2039/0276
A A61 A61M2205/04

Field of Art

Biomedical engineering focused on implantable drug delivery systems, specifically nanoporous medical devices for controlled release of therapeutic agents, requiring expertise in materials science, nanotechnology, and biomedical device design

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or materials scientist with advanced degree, experience in nanofabrication techniques, understanding of biomaterial interactions, and knowledge of controlled drug delivery mechanisms

Obviousness Rationale

A person having ordinary skill would recognize that the PTD's variations represent predictable engineering improvements to the source patent's fundamental nanoporous implantable canister design. The disclosed modifications of dynamic pore sizing, 3D printing customization, and integrated monitoring represent logical extensions of the original patent's core technological concept of controlled therapeutic agent delivery. These variations would be considered routine optimization techniques within the capabilities of a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
Nanoscale through-porous structure with pores between 20-5000 nm
PTD Variation
Dynamically adjustable pore size responsive to tissue environment
Obviousness Reasoning
A PHOSITA would recognize that controlling pore size is a predictable design parameter for modulating agent diffusion, representing an obvious engineering solution for improving controlled release mechanisms
Source Patent Element
Metallic shell configured for controlled secretion of metabolically active agent
PTD Variation
3D printed customized pore structure with patient-specific geometries
Obviousness Reasoning
Advanced manufacturing techniques like 3D printing represent a known method for creating patient-specific medical devices, constituting an obvious design choice for personalizing implantable drug delivery systems
Source Patent Element
Implantable canister with interior chamber for stabilizing metabolically active agents
PTD Variation
Nanoscale bicontinuous morphology promoting cellular adhesion and tissue integration
Obviousness Reasoning
Surface modification to enhance biocompatibility is a standard approach in medical device design, representing a predictable solution for improving implant performance and tissue interaction
Source Patent Element
Nanoporous structure defining diffusion channels for metabolic agents
PTD Variation
Integrated microfluidic channel for real-time monitoring of agent release
Obviousness Reasoning
Adding sensor capabilities to monitor drug delivery is an obvious technological enhancement that would be expected by a skilled practitioner seeking to improve device functionality
Source Patent Element
Metallic shell with nanoscale through-porous structure
PTD Variation
Self-healing mechanism for repairing nanoporous structure damage
Obviousness Reasoning
Implementing self-repair mechanisms in nanomaterials represents a known strategy for maintaining device integrity, constituting an obvious design improvement for maintaining consistent drug delivery performance
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857670 and the disclosed technical variations, a person having ordinary skill in the art would find the claimed innovations of the advanced implantable canister system obvious and therefore unpatentable. The modifications represent predictable engineering solutions that would be apparent to a skilled practitioner seeking to optimize controlled therapeutic agent delivery through incremental technological improvements.

Original Patent Information

Patent NumberUS 11,857,670
TitleImplantable cellular and biotherapeutic agent delivery canister
Assignee(s)NanoVault Medical LLC